Pawel Mroz, MD, PhD

Assistant Professor, Department of Laboratory Medicine and Pathology

Pawel Mroz

Contact Info

Office Phone 612-624-6168

Office Address:
MMC 198 Mayo

Mailing Address:
8198A (Campus Delivery Code)
420 Delaware St SE
Minneapolis, MN 55455

MD, Medical University of Warsaw, 2004

PhD, Doctor of Philosophy in Medicine (Honors), Medical University of Warsaw, 2008

Instructor, Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, 2008-2011

Residency in AP/CP, Department of Pathology, Feinberg School of Medicine, Northwestern University, 2015

Hematopathology Fellow, Department of Pathology, University of Michigan, 2016

Molecular Genetic Pathology Fellow, Department of Pathology, University of Michigan, 2017


Dr. Pawel Mroz is a member of the department’s Division of Molecular Pathology and Genomics. He is board certified in anatomic and clinical pathology with expertise in hematopathology and molecular genetic pathology and he will provide primary service in the Molecular Diagnostic Laboratory as well as hematopathology.

Dr Mroz’s early research interests included translational applications of photodynamic therapy for cancer treatment as well as investigating the role of tumor associated antigens and T regulatory cells in anti-tumor immune response.

Currently his research interests are focused on two areas: Droplet digital polymerase chain reaction (ddPCR) and next-generation sequencing (NGS) technologies. Droplet digital PCR (ddPCR) is a novel diagnostic platform that provides absolute quantification of amplification targets by partitioning and separately analyzing each PCR reaction. ddPCR is a refinement of conventional and quantitative PCR as it demonstrates robust performance characteristics and may offer improved detection of low-level disease. ddPCR has the potential to become an especially valuable diagnostic and prognostic tool in hematologic malignancies like acute lymphoblastic leukemia or acute myeloid leukemia as it may allow for earlier detection of relapse or persistence of disease.

Next-generation DNA sequencing is beginning to be applied in the initial diagnosis and classification of a growing number of malignancies. Dr Mroz has experience in the clinical application of NGS but wants to focus on developing new translational applications for NGS in the research setting that over time can be brought to the clinic. The technical dimension of NGS is fairly well understood but its use in characterizing hematologic malignancies is at an early stage of development. Dr Mroz sees opportunities for adding new NGS applications for better characterization and classification of hematologic malignancies.



Recent Publications

Salloum RG, Bishop JR, Elchynski AL, Smith DM, Rowe E, Blake KV, Limdi NA, Aquilante CL, Bates J, Beitelshees AL, Cipriani A, Duong BQ, Empey PE, Formea CM, Hicks JK, Mroz P, Oslin D, Pasternak AL, Petry N, Ramsey LB, Schlichte A, Swain SM, Ward KM, Wiisanen K, Skaar TC, Van Driest SL, Cavallari LH, Tuteja S.Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy. Implement Sci Commun. 2022 May 14;3(1):52. doi: 10.1186/s43058-022-00300-7.

Mroz P, Michel S, Allen JD, Meyer T, McGonagle EJ, Carpentier R, Vecchia A, Schlichte A, Bishop JR, Dunnenberger HM, Yohe S, Thyagarajan B, Jacobson PA, Johnson SG. Development and implementation of in-house pharmacogenomic testing program at a major academic health system. Front Genet. 2021 Oct 20;12:712602. doi: 10.3389/fgene.2021.712602.

Oltvai ZN, Harley SE, Koes D, Michel S, Warlick ED, Nelson AC, Yohe S, Mroz P. Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling. Cold Spring Harb Mol Case Stud. 2021 Apr 8;7(2):a006007.  doi: 10.1101/mcs.a006007.

Ryan J. Martinez, Qing Kang, Davis Nennig, Nathanael G. Bailey, Noah A. Brown, Bryan L. Betz, Muneesh Tewari, Bharat Thyagarajan, Veronika Bachanova, Pawel Mroz.  One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia.Arch Pathol Lab Med2021; doi:

Fujiyoshi K, Bruford EA, Mroz P, Sims CL, O'Leary TJ, Lo AWI, Chen N, Patel NR, Patel KP, Seliger B, Song M, Monzon FA, Carter AB, Gulley ML, Mockus SM, Phung TL, Feilotter H, Williams HE, Ogino S.  Opinion: Standardizing gene product nomenclature-a call to action. Proc Natl Acad Sci U S A. 2021 Jan 19;118(3):e2025207118. doi 10.1073/pnas.2025207118.

Wachowska M, Gabrysiak M, Muchowicz A, Bednarek W, Barankiewicz J, Rygiel T, Boon L, Mroz P, Hamblin MR, Golab J. 5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. Eur J Cancer. 2014 May;50(7):1370-81. 

Xia, Y, Gupta GK, Castano AP, Mroz P, Avci P and Hamblin MR. CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer. J Biophotonics. 2014 Nov;7(11-12):897-905. 

Mroz, P, Vatansever F, Szokalska A, and Hamblin, M.R. Photodynamic therapy of murine mastocytoma induces specific immune response to P1A, a naturally occurring mouse cancer/testis antigen.  Cancer Res. 2013 Nov 1;73(21):6462-70.

Reginato E, Mroz P, Chung H, Kawakubo M, Wolf P, Hamblin MR. Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen. Br J Cancer. 2013 Oct 15;109(8):2167-74.

Tanaka M, Mroz P, Dai T, Huang L, Morimoto Y, Kinoshita M, Yoshihara Y, Shinomiya N, Seki S, Nemoto K, Hamblin MR. Linezolid and vancomycin decrease the therapeutic effect of methylene blue-photodynamic therapy in a mouse model of MRSA bacterial arthritis. Photochem Photobiol. 2013 May-Jun;89(3):679-82. 

Garci?a-Di?az M, Kawakubo M, Mroz P, Sagrista? ML, Mora M, Nonell S, Hamblin MR. Cellular and vascular effects of the photodynamic agent temocene are modulated by the delivery vehicle. J Control Release. 2012 Sep 10;162(2):355-63. 

Tanaka M, Mroz P, Dai T, Huang L, Morimoto Y, Kinoshita M, Yoshihara Y, Nemoto K, Shinomiya N, Seki S, Hamblin MR. Photodynamic therapy can induce a protective innate immune response against murine bacterial arthritis via neutrophil accumulation. PLoS One. 2012;7(6):e39823. 

Udayakumar D, Zhang G, Njauw CN, Mroz P, Ji Z, Tsao H. EphA2 is a Critical Oncogene in Melanoma. Oncogene. 2011 Dec 15;30(50):4921-9. 

Mroz P, Xia Y, Asanuma D, Konopko A, Zhiyentayev T, Huang Y-Y, Sharma S.K., Dai T, Khan U.J., Wharton T, Hamblin M.R., Intraperitoneal Photodynamic therapy with functionalized fullerenes. Nanomedicine 2011 Dec;7(6):965-74 

Mroz, P, Szokalska A, Wu M.X, and Hamblin M.R. Photodynamic Therapy of Tumors Can Lead to Development of Systemic Antigen-Specific Immune Response. Plos One 2010 Dec 14;5(12):e15194 


Board Certifications

Anatomic Pathology; Clinical Pathology; Hematopathology; Molecular Genetic Pathology